ISTA Pharmaceuticals Highlights BEPREVE(R) Clinical Data At The 2011 American Academy Of Allergy, Asthma And Immunology (AAAAI) Annual Meeting

ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), today announced additional results from the Company's BEPREVE(R) (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies in allergic conjunctivitis. These results were presented in poster sessions at the 2011 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in San Francisco, CA.